INVESTMENT OPPORTUNITY

Investment Opportunity(1001)

Establishment of a Medical Solutions Manufacturing Plant

Project Overview

The **Ministry of Investment** is offering a strategic investment opportunity to establish an integrated manufacturing plant for medical solutions (intravenous fluids) within the Industrial City in Benghazi. This project aims to support national drug security, reduce reliance on imports, and enhance local industrial capabilities in the pharmaceutical and medical supplies sector.

The project is designed to produce various types of medical solutions in compliance with Good Manufacturing Practices (GMP) and approved international standards. This will fulfill the requirements of hospitals, healthcare centers, and clinics across Libya, while also enabling export to regional and African markets.

Project Location & Nature

- **Location:** Industrial City, Benghazi – State of Libya.
- **Sector:** Pharmaceuticals & Medical Supplies.
- **Project Nature:** Fully integrated strategic project.

Target Markets

- The Libyan Domestic Market.
- Public and Private Hospitals.
- Specialized Medical Centers and Clinics.
- North African Markets.
- The African Sahel Countries.
- Regional and Arab Markets.

Land Area Requirements

Component	Required Area
Total Plot Area	40,000 – 60,000 m^2
Production & Packaging Zone	15,000 – 20,000 m^2
Storage & Logistics Facilities	10,000 – 15,000 m^2
Future Expansions & Ancillary Utilities	Remaining Balance

Estimated Investment Capital

Cost Component	Value (USD)
Infrastructure & Civil Works	$8 – $12 Million
Sterile Production & Packaging Lines	$20 – $35 Million
Laboratories & Quality Control Systems	$5 – $8 Million
Storage & Logistics Facilities	$3 – $5 Million
Pre-operating & Working Capital	$5 – $10 Million
Total Investment Cost	$41 – $70 Million

Project Components

- Intravenous (IV) Solutions production lines.
- Packaging lines for plastic bottles and medical bags.
- Water for Injection (WFI) treatment and purification systems.
- Advanced sterilization and disinfection systems.
- Quality control (QC) and microbiological testing laboratories.
- Raw material and finished product warehouses.
- Advanced digital control and operating systems.
- Integrated administrative and service facilities.
- Comprehensive medical, industrial safety, and security systems.

Core Products

- Normal Saline (Sodium Chloride Solution).
- Medical Glucose Solutions.
- Ringer's Lactate Solution.
- Multi-purpose Intravenous Fluids.
- Medical Irrigation and Disinfection Solutions.
- Specialized Solutions for ICU and Emergency Units.

Product Applications

- Public and Private Hospitals.
- Health Centers and Medical Clinics.
- Operating Rooms (OR) and Intensive Care Units (ICU).
- Emergency and Ambulance Departments.
- Dialysis Centers.
- Military and Public Medical Institutions.

Estimated Production Capacity

- Annual production of **80 to 120 million units** of medical solutions.
- Production of various volumes and concentrations tailored to healthcare sector needs.
- Flexibility for future expansions to produce additional sterile pharmaceutical preparations.
- Output strictly compliant with GMP guidelines and international pharmacopeia standards.

Financial Indicators

Financial Metric	Projected Value
Expected Annual Revenue	$40 – $90 Million
Net Annual Profit	$8 – $18 Million
Return on Investment (ROI)	14% – 22%
Payback Period	4 – 6 Years
Operating Profit Margin	18% – 28%

Competitive Advantages

- Meeting the steadily growing domestic demand for medical solutions.
- Reducing dependency on foreign imports.
- Strategic proximity to the Port of Benghazi and major transport networks.
- Low shipping and supply chain costs for the local market.
- High potential for exporting to neighboring African markets.
- Strict adherence to international pharmaceutical standards.
- Strengthening national health security and sovereign pharmaceutical production.

Job Creation

- **Direct Jobs:** 250 – 450 positions.
- **Indirect Jobs:** 800 – 1,500 positions.
- **Construction Phase Jobs:** 400 – 700 temporary positions.

Available Contractual Models

The Ministry of Investment offers investors flexibility through various business models, including:

- Direct Investment (FDI/Local).
- Partnership with the Libyan Private Sector.
- Partnership with the Public Sector.
- Joint Ventures (JV).
- Public-Private Partnerships (PPP).
- Build-Operate-Transfer (BOT).
- Build-Own-Operate (BOO).
- Management and Operation Contracts.

Investment Incentives & Privileges

The project qualifies for comprehensive incentives, exemptions, and guarantees stipulated under the **Investment Promotion Law No. (9) of 2010**, notably:

- Full exemption from customs duties on machinery, equipment, and pharmaceutical production lines.
- Tax exemptions designated for strategic industrial projects.
- Streamlined land allocation processes within designated industrial zones.
- Freedom to repatriate profits and invested capital in accordance with applicable regulations.

- Expedited licensing and approval processes dedicated to pharmaceutical industries.
- Direct state support for projects linked to national medical and drug security.
- Priority in national programs aimed at localizing medical industries in Libya.

Technical & Economic Feasibility Services

Should the investor wish to obtain a comprehensive technical, economic, and financial feasibility study aligned with accredited international standards, specialized advisory offices are available through the Ministry of Investment and its partners. The fee for preparing the final definitive feasibility study is **1.5% of the total investment value** of the project.

Invitation to Invest

The Ministry of Investment cordially invites local and international investors, specialized pharmaceutical and medical supply companies, health tech firms, investment funds, and financial institutions to participate in this strategic venture.

This project represents a pivotal opportunity to fortify drug security in Libya, localize advanced medical manufacturing, reduce the import bill, and increase the industrial sector's contribution to the national economy—ultimately driving sustainable development and positioning Libya as a regional hub for pharmaceutical industries and healthcare services in North Africa.

MINISTRY OF INVESTMENT -*State of Libya*